Gamal N, Brodosi L, Misciali C, Patrizi A, Vukatana G, Malavolta N, Bernardi M, Andreone P

Language: English
References: 29
Page: 293-296
PDF size: 108.17 Kb.

ABSTRACT

For the last decade, the combination therapy of pegylated interferon (Peg-IFN) plus ribavirin (RBV) has been considered as the standard of care treatment for chronic hepatitis C virus (HCV) infection. However, it has been associated with an increased incidence of many adverse cutaneous reactions and emergence of autoantibodies or even autoimmune diseases. We report a case of irreversible alopecia universalis (AU) with complete hair loss extended to the whole body, which started after discontinuation of Peg-IFN/RBV combination therapy for chronic HCV infection. In conclusion, this case represents an uncommon presentation of a common disease. Physicians must be aware of the potential adverse reactions of an antiviral therapy containing IFN, which might occur even after the discontinuation, and fully inform the patient at the beginning of his treatment course. We hope that interferon-free regimens will utterly supplant interferon- based therapy for most or all HCV patients avoiding the emergence of autoimmune manifestations.

REFERENCES

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.

2. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012; 12: 717-28.

3. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.

4. Aspinall RJ, Pockros PJ. Review article: the management of side effects during therapy for hepatitis C. Aliment Pharmacol Ther 2004; 20: 917-29.

5. Vial T, Descotes J. Immune-mediated side effects of cytokines in humans. Toxicology 1995; 105: 31-57.

6. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010; 62: 177-88.

7. Rachita Dhurat, Punit Saraogi. Hair Evaluation Methods: Merits and Demerits. Int J Trichology 2009; 1: 108-19.

8. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol 2002; 27: 405-9.

9. Alexis AF, Dudda-Subramanya R, Sinha AA. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 2004; 14: 364-70.

10. Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a survey analysis of patient and family. Int J Dermatol 1992; 31: 186-9.

11. Elder DE, Elenitsas R, Johnson BL, et al. Alopecia areata. In: Lever’s Histopatholgy of the Skin. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2005, p. 483-5.

12. Sookoian S, Neglia V, Castano G, Frider B, Kien MC, Chohuela E. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 1999; 135: 1000-1.

13. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol 2009; 23: 677-83.

14. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: 237-44.

15. Jadali Z. Dermatologic manifestations of hepatitis C infection and the effect of interferon therapy: a literature review. Arch Iran Med 2012; 15: 43-8.

16. Trapero M, García-Buey L, Muñoz C, Vitón M, Moreno- Monteagudo JA, Borque MJ, Quintana NE, Moreno-Otero R. Maintenance of T1 response as induced during PEGIFNalpha plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev Esp Enferm Dig 2005; 97: 481-90.

17. Teraki Y, Imanishi K, Shiohara T. Cytokines in alopecia areata: contrasting cytokine profiles in localized form and extensive form (alopecia universalis). Acta Derm Venereol 1996; 76: 421-3.

18. Gregoriou S, Papafragkaki D, Kontochristopoulos G, Rallis E, Kalogeromitros D, Rigopoulos D. Cytokines and other mediators in alopecia areata. Mediators Inflamm 2010. Doi: 10.1155/2010/928030.

19. Tobin DJ. Characterization of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc 2003; 8: 176-81.

20. Gilhar A, Pillar T, Assy B, David M. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br J Dermatol 1992; 126: 166-71.

21. Amos Gilhar, Amos Etzioni, Ralf Paus. Alopecia areata. N Engl J Med 2012; 366: 1515-25.

22. Harries MJ, Sun J, Paus R, King LE Jr. Management of alopecia areata. BMJ 2010; 341: c3671.

23. Lang AM, Norland AM, Schuneman RL, Tope WD. Localized interferon alfa-2b-induced alopecia. Arch Dermatol 1999; 135: 1126-8.

24. Shafa S, Borum ML, Iglehon E. A case of irreversible alopecia associated with ribavirin and peg-interferon therapy. Eur J Gastroenterol Hepatol 2010; 22: 122-3.

25. Taliani G, Biliotti E, Capanni M, et al. Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C. J Chemother 2005; 17: 212-4.

26. Kartal ED, Alpat SN, Ozgunes I, et al. Reversible alopecia universalis secondary to PEG-interferon a-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2007; 19: 817-20.

27. Demirturk N, Aykin N, Demirdal T, et al. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Eur J Dermatol 2006; 16: 579-94.

28. Midian-Singh R, Alagugurusamy S, Agrawal R. Alopecia universalis following interferon Alfa-2b and ribavirin treatment for hepatitis C. Gastroenterol Hepatol 2007; 3: 644-5.

29. Omazzi B, Prada A, Borroni G, Sacrini F. Irreversible alopecia universalis during treatment with pegylated interferon- ribavirin for chronic hepatitis C virus infection: Case report and published work review. Hepatol Res 2012; 42: 1248-51.